Journal article

Anti-CD2 producing pig xenografts effect localized depletion of human T cells in a huSCID model

Jamie L Brady, Robyn M Sutherland, Manuela Hancock, Susie Kitsoulis, Mireille H Lahoud, Peta M Phillips, Wayne J Hawthorne, Anthony JF d'Apice, Peter J Cowan, Leonard C Harrison, Philip J O'Connell, Andrew M Lew

XENOTRANSPLANTATION | WILEY-BLACKWELL | Published : 2013

Abstract

BACKGROUND: We investigated whether graft produced anti-human CD2, mediated by adenovirus (Adv) transduction of pig neonatal islet cell clusters (pNICC), would protect xenografts in a humanized mouse model from immune attack and whether such immunosuppression would remain local. METHODS: A mouse anti-human CD2 Ab (CD2hb11) previously generated by us was genetically engineered to produce chimeric and humanized versions. The three forms of CD2hb11 were named dilimomab (mouse), diliximab (chimeric) and dilizumab (humanized). All 3 forms of CD2hb11 Ab were tested for their ability to bind CD3(+) human T cells and to inhibit a human anti-pig xenogeneic mixed lymphocyte reaction (MLR). They were a..

View full abstract

Grants

Awarded by Juvenile Diabetes Research Foundation


Awarded by Australian National Health and Medical Research Council


Funding Acknowledgements

This work was made possible through Victorian State Government Operational Infrastructure Support and Australian Government NHMRC IRIIS. This work was supported by the Juvenile Diabetes Research Foundation (ID 447718), Australian National Health and Medical Research Council (ID 516700), and the Rebecca L. Cooper Foundation.